A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
Completed
Debiopharm International SA
Phase 2
Debio 025 (alisporivir) is an oral cyclophilin inhibitor with a new mechanism of action
demonstrating potent anti-hepatitis C virus (HCV) activity in pre-clinical models and
patients.
The current standard of care (SOC) in HCV patients consists of a combination of peg-IFN alpha
and ribavirin. Treatment duration and ribavirin dose depend on the genotype treated. Only
40-50% of patients with genotype 1 achieve a sustained viral response (SVR). This study
assesses whether Debio 025 administered in combination with peg-IFN alpha 2a and ribavirin
can improve the outcome of treatment in this group of patients.
A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients
Completed
Parexel
N/A
The purpose of this study is to compare several Debio 025 (alisporivir)/peg-IFNα2a/ribavirin
triple therapies with the current standard of care (SOC) in treatment naïve chronic hepatitis
C genotype 1 patients.
A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients
Completed
Debiopharm International SA
N/A
The purpose of this study is to compare several Debio 025 (alisporivir)/peg-IFNα2a/ribavirin
triple therapies with the current standard of care (SOC) in treatment naïve chronic hepatitis
C genotype 1 patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
